Compare American International Group Inc (AIG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs Inovio Pharmaceuticals Inc — how do they compare? American International Group Inc trades at $76.32 (market cap $40.42B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: American International Group Inc is far larger — about 514.6× Inovio Pharmaceuticals Inc's market cap, and American International Group Inc pays a 2.59% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AIG | INO | |
|---|---|---|
Market Cap | $40.42B | $78.55M |
Sector | Financials | Health |
52-Week High | $86.59 | $2.87 |
52-Week Low | $71.89 | $0.66 |
Enterprise Value | $48.06B | $49.56M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $77.61, down 1.49% today, with a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.00 exceeding the $1.92 estimate. The company maintains solid profitability with an 11.12% net income margin and a P/E of 14.11, indicating reasonable valuation. Cash flow from operations remains positive at $3.31 billion for 2025, supporting dividend payments of $0.50 per share.
The outlook is mixed; analyst consensus is a Buy with a $89.00 price target, suggesting 14.7% upside, but technical indicators signal near-term caution. Risks include competitive pricing pressure and geopolitical exposures, while opportunities lie in disciplined underwriting and AI integration. Investor sentiment is cautiously optimistic amid steady premium growth and expense control.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
